Posaconazole NDC 71335-2930

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-2930Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-2930Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71335-2930-1	71335293001	60 TABLET, DELAYED RELEASE in 1 BOTTLE (71335-2930-1)Marketed from Nov 11, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Posaconazole
Generic name (nonproprietary): posaconazole
Active ingredients: Posaconazole — 100 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216488
Marketing start: Sep 15, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Azoles (Chemical structure)
Identifiers: Product ID 71335-2930_aa780d7b-d64f-4642-8096-a4a9e474c356SPL ID aa780d7b-d64f-4642-8096-a4a9e474c356SPL set ID f15fc7d4-04ea-4be5-bfed-9a8bae74591cRxCUI 1482908UNII 6TK1G07BHZ
Pharmacologic class: Azole Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335293001 followed by a unit qualifier and the quantity

Package 71335-2930-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 11, 2025.

Indications (excerpt from the label)

Posaconazole is an azole antifungal indicated as follows: Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus- host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets: adults and pediatric patients 13 years of age and older. 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216488

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216488
Product	Strength	Form · route	Labeler	Product NDC
Posaconazole	Posaconazole 100 mg/1	Tablet, Delayed releaseOral	A2A Integrated Pharmaceuticals	73141-023
Posaconazole	Posaconazole 100 mg/1	Tablet, Delayed releaseOral	i3 Pharmaceuticals, LLC	72319-023
Posaconazole	Posaconazole 100 mg/1	Tablet, Delayed releaseOral	Bryant Ranch Prepack	71335-2665
Posaconazole	Posaconazole 100 mg/1	Tablet, Delayed releaseOral	Bryant Ranch Prepack	72162-2243